sábado, 25 de noviembre de 2017

Neutralizing Antibodies to Influenza HA and Their Use and Identification | Office of Technology Transfer, NIH

Neutralizing Antibodies to Influenza HA and Their Use and Identification | Office of Technology Transfer, NIH



Drug development opportunity: Antibodies that may treat and prevent the flu

TTIPO Flu Image 1

(Left) Co-crystal structure of Fab 56.a.09 in complex with an H3 HA monomer (A/Hong Kong/1-4-MA21-1/1968). Fab heavy and light chains colored purple and cyan respectively and depicted in surface representation, while the H3 HA is depicted in ribbon and shown as a trimer. (Right) Interacting CDR loops of the 56.a.09 Fab are shown in ribbon and sticks with the antibody footprint outlined. Photo Credit: NIAID



NIAID investigators isolated antibodies that may be able to treat severe influenza infections and prevent infection in vulnerable populations during an outbreak. These unique antibodies react with regions of the virus that change the least from season to season, meaning they could be effective against a variety of influenza strains annually. Read more about this exciting collaboration/licensing opportunity at https://www.ott.nih.gov/technology/e-061-2016

No hay comentarios:

Publicar un comentario